Research programme: antioxidants - Activus Pharma

Drug Profile

Research programme: antioxidants - Activus Pharma

Alternative Names: TA-264; TA-381

Latest Information Update: 22 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Activus Pharma
  • Developer Sosei
  • Class Quinolones
  • Mechanism of Action Antifibrinolytic agents; Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Peripheral vascular disorders; Stroke

Most Recent Events

  • 17 Aug 2010 Activus Pharma has been acquired and merged into Sosei
  • 17 Aug 2010 Activus Pharma has been acquired by Sosei
  • 21 Jun 2010 Sosei agrees to acquire Activus Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top